3-(氰基甲基)-1,3-哌啶二羧酸-1-(1,1-二甲基乙基)3-乙酯 | 923009-49-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 3-(氰基甲基)-1,3-哌啶二羧酸-1-(1,1-二甲基乙基)3-乙酯
• 英文名称: 1-(tert-butyl) 3-ethyl 3-(cyanomethyl)piperidine-1,3-dicarboxylate
• 英文别名: 3-ethyl 1-tert-butyl 3-(cyanomethyl)piperidine-1,3-dicarboxylate；1-Tert-butyl 3-ethyl 3-(cyanomethyl)piperidine-1,3-dicarboxylate；1-O-tert-butyl 3-O-ethyl 3-(cyanomethyl)piperidine-1,3-dicarboxylate
• CAS: 923009-49-8
• 化学式: C₁₅H₂₄N₂O₄
• 分子量: 296.367
• InChiKey: FHDJXVYVZDYORH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  79.6
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  3-(氰基甲基)-1,3-哌啶二羧酸-1-(1,1-二甲基乙基)3-乙酯 在 盐酸 作用下， 以 乙酸乙酯 为溶剂， 生成 Ethyl 3-(cyanomethyl)piperidine-3-carboxylate
  参考文献：
  名称：

  Design, synthesis, and structure–activity relationships of novel spiro-piperidines as acetyl-CoA carboxylase inhibitors

  摘要：

  Spiro-lactone (S)-1 is a potent acetyl-CoA carboxylase (ACC) inhibitor and was found to be metabolically liable in human hepatic microsomes. To remove one of the risk factors in human study by improving the metabolic stability, we focused on modifying the spiro-lactone ring and the benzothiophene portion of the molecule. Spiro-imide derivative 8c containing a 6-methylthieno[2,3-b]pyridine core exhibited potent ACC inhibitory activity and favorable pharmacokinetic profiles in rats. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.04.047
• 作为产物：
  描述：

  二碳酸二叔丁酯 在 三乙胺 、 lithium hexamethyldisilazane 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 反应 21.42h， 生成 3-(氰基甲基)-1,3-哌啶二羧酸-1-(1,1-二甲基乙基)3-乙酯
  参考文献：
  名称：

  [EN] SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
  [FR] MODULATEURS SPIRO-LACTAMES DES RÉCEPTEURS NMDA ET LEURS UTILISATIONS

  摘要：

  揭示了具有调节NMDA受体活性潜力的化合物。这些化合物可用于治疗抑郁症和相关疾病。还披露了口服制剂和其他药学上可接受的化合物给药形式，包括静脉注射制剂。

  公开号：

  WO2018026779A1

文献信息

• SPIRO-RING COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP2128163A1

  公开（公告）日：2009-12-02

  The present invention aims to provide a compound having an acetyl-CoA carboxylase (ACC) inhibitory action, which is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia, cancer and the like, and has superior efficacy. The present invention provides a compound represented by the formula (I): wherein R1 is a hydrogen atom or a substituent; ring P is an optionally substituted 6-membered nitrogen-containing aromatic heterocycle; ring Q is an optionally further substituted 5- to 7-membered nitrogen-containing non-aromatic heterocycle; and ring R is an optionally fused 5- to 7-membered non-aromatic ring, which is further optionally substituted, or a salt thereof.

  本发明旨在提供一种具有乙酰辅酶A羧化酶（ACC）抑制作用的化合物，该化合物对于预防或治疗肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌少症、癌症等具有卓越疗效。 本发明提供一种由以下式（I）表示的化合物： 其中 R1是氢原子或取代基； 环P是可选择取代的含氮芳香杂环； 环Q是可选择进一步取代的5-至7-成员的含氮非芳香杂环；和 环R是可选择融合的5-至7-成员的非芳香环，进一步可选择取代， 或其盐。
• SPIRO-CYCLIC COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP1911753A1

  公开（公告）日：2008-04-16

  The present invention provides a compound represented by the formula (I): wherein E is an optionally substituted cyclic group; D is a carbonyl group or a sulfonyl group; A is CH or N; ring P is an optionally further substituted 5- to 7-membered ring; ring Q is an optionally further substituted 5- to 7-membered nonaromatic ring; and ring R is an optionally further substituted and optionally condensed 5- to 7-membered nonaromatic ring, or a salt thereof. The compound of the present invention has an ACC inhibitory activity, is useful for the prophylaxis or treatment of obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and has superior properties in the efficacy, duration of activity, specificity, low toxicity and the like.

  本发明提供了一种由以下式（I）表示的化合物： 其中 E是一个可选择地取代的环状基团； D是一个羰基团或磺酰基团； A是CH或N； 环P是一个可选择进一步取代的5至7元环； 环Q是一个可选择进一步取代的5至7元非芳香环； 环R是一个可选择进一步取代和可选择缩合的5至7元非芳香环，或其盐。本发明的化合物具有ACC抑制活性，对于肥胖、糖尿病、高血压、高脂血症、心力衰竭、糖尿病并发症、代谢综合征、肌肉萎缩等的预防或治疗具有用处，并且在功效、持续活性、特异性、低毒性等方面具有优越性能。
• Spiro-lactam NMDA receptor modulators and uses thereof
  申请人：Aptinyx Inc.

  公开号：US11299495B2

  公开（公告）日：2022-04-12

  Disclosed are compounds having potency in the modulation of NMDA receptor activity. Such compounds can be used in the treatment of conditions such as depression and related disorders. Orally delivered formulations and other pharmaceutically acceptable delivery forms of the compounds, including intravenous formulations, are also disclosed.

  所公开的化合物具有调节 NMDA 受体活性的功效。此类化合物可用于治疗抑郁症及相关疾病。此外，还公开了口服制剂和其他药学上可接受的化合物给药形式，包括静脉注射制剂。
• Design, synthesis, and structure–activity relationships of spirolactones bearing 2-ureidobenzothiophene as acetyl-CoA carboxylases inhibitors
  作者：Tohru Yamashita、Makoto Kamata、Satoshi Endo、Mitsuo Yamamoto、Keiko Kakegawa、Hiroyuki Watanabe、Katsuhiko Miwa、Toru Yamano、Masaaki Funata、Jyun-ichi Sakamoto、Akiyoshi Tani、Clifford D. Mol、Hua Zou、Douglas R. Dougan、BiChing Sang、Gyorgy Snell、Kohji Fukatsu

  DOI：10.1016/j.bmcl.2011.08.117

  日期：2011.11

  The co-crystal structure of the human acetyl-coenzyme A 2 (ACC2) carboxyl transferase domain and the reported compound CP-640186 (1b) suggested that two carbonyl groups are essential for potent ACC2 inhibition. By focusing on enhancing the interactions between the two carbonyl groups and the amino acid residues Gly(2162) and Glu(2230), we used ligand-and structure-based drug design to discover spirolactones bearing a 2-ureidobenzothiophene moiety (C) 2011 Elsevier Ltd. All rights reserved.
• SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF
  申请人：Aptinyx Inc.

  公开号：EP3490992A1

  公开（公告）日：2019-06-05